TIAA CREF Investment Management LLC Has $134.91 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

TIAA CREF Investment Management LLC lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.6% during the first quarter, according to its most recent filing with the SEC. The fund owned 735,448 shares of the medical instruments supplier’s stock after selling 125,359 shares during the period. TIAA CREF Investment Management LLC owned about 0.34% of Becton, Dickinson and worth $134,911,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Teachers Advisors LLC raised its position in Becton, Dickinson and by 4.0% in the first quarter. Teachers Advisors LLC now owns 360,409 shares of the medical instruments supplier’s stock worth $66,113,000 after buying an additional 13,836 shares in the last quarter. Homrich & Berg raised its position in Becton, Dickinson and by 3.6% in the first quarter. Homrich & Berg now owns 3,532 shares of the medical instruments supplier’s stock worth $648,000 after buying an additional 122 shares in the last quarter. Advantus Capital Management Inc raised its position in Becton, Dickinson and by 0.7% in the first quarter. Advantus Capital Management Inc now owns 21,513 shares of the medical instruments supplier’s stock worth $3,946,000 after buying an additional 144 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Becton, Dickinson and by 1.8% in the first quarter. Principal Financial Group Inc. now owns 318,741 shares of the medical instruments supplier’s stock valued at $58,470,000 after buying an additional 5,514 shares during the period. Finally, TLP Group LLC raised its position in shares of Becton, Dickinson and by 42.0% in the first quarter. TLP Group LLC now owns 1,600 shares of the medical instruments supplier’s stock valued at $294,000 after buying an additional 473 shares during the period. Hedge funds and other institutional investors own 75.57% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) traded down 0.81% during trading on Friday, reaching $197.69. The company’s stock had a trading volume of 989,225 shares. The stock’s 50 day moving average is $199.72 and its 200 day moving average is $188.69. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The company has a market cap of $44.99 billion, a price-to-earnings ratio of 57.25 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.35 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s payout ratio is currently 83.43%.

WARNING: This story was published by BNB Daily and is owned by of BNB Daily. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/tiaa-cref-investment-management-llc-decreases-stake-in-becton-dickinson-and-company-nysebdx-updated-updated-updated.html.

BDX has been the topic of several research reports. Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $186.00 to $200.00 in a report on Monday, April 24th. Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their price target for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Cowen and Company restated an “outperform” rating and issued a $230.00 price target (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. Finally, BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $195.79.

In related news, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the sale, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now directly owns 70,821 shares in the company, valued at $13,171,289.58. The disclosure for this sale can be found here. Insiders sold 57,631 shares of company stock worth $11,112,178 in the last quarter. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply